Cargando…
Characterization of TR‐107, a novel chemical activator of the human mitochondrial protease ClpP
We recently described the identification of a new class of small‐molecule activators of the mitochondrial protease ClpP. These compounds synthesized by Madera Therapeutics showed increased potency of cancer growth inhibition over the related compound ONC201. In this study, we describe chemical optim...
Autores principales: | Fennell, Emily M. J., Aponte‐Collazo, Lucas J., Wynn, Joshua D., Drizyte‐Miller, Kristina, Leung, Elisa, Greer, Yoshimi Endo, Graves, Paul R., Iwanowicz, Andrew A., Ashamalla, Hani, Holmuhamedov, Ekhson, Lang, Henk, Karanewsky, Donald S., Der, Channing J., Houry, Walid A., Lipkowitz, Stanley, Iwanowicz, Edwin J., Graves, Lee M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354705/ https://www.ncbi.nlm.nih.gov/pubmed/35929764 http://dx.doi.org/10.1002/prp2.993 |
Ejemplares similares
-
Mitochondrial Protease ClpP is a Target for the Anticancer
Compounds ONC201 and Related Analogues
por: Graves, Paul R., et al.
Publicado: (2019) -
Correction to
“Mitochondrial Protease ClpP
Is a Target for the Anticancer Compounds ONC201 and Related Analogues”
por: Graves, Paul R., et al.
Publicado: (2022) -
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
por: Fennell, Emily M. J., et al.
Publicado: (2023) -
The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021) -
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis
por: Greer, Yoshimi Endo, et al.
Publicado: (2022)